Aslan Pharmaceuticals Company Overview
About Aslan Pharmaceuticals
Aslan Pharmaceuticals ADR (NASDAQ:ASLN) is a biotech company focused on developing innovative treatments for patients suffering from cancer and autoimmune diseases. The company's portfolio includes projects that target diseases with significant unmet medical needs, employing a science-driven approach to discover and develop novel therapeutics. Aslan Pharmaceuticals is known for its dedication to improving patient outcomes by advancing a range of candidates through clinical trials, with the aim to offer new, effective treatment options. The company's objectives are centered around accelerating the development of its pipeline products, expanding its research to cover more diseases, and ultimately making a substantial impact on patient care globally.
Snapshot
Operations
Products and/or services of Aslan Pharmaceuticals
- Developing varlitinib, a potent pan-HER inhibitor aimed at treating biliary tract cancer.
- Efgartigimod, an antibody fragment for immunoglobulin G (IgG) mediated diseases, in partnership.
- ASLAN004, a monoclonal antibody for atopic dermatitis and other allergic conditions.
- Pursuing next-generation treatments for autoimmune diseases with novel therapeutic targets.
- Investing in preclinical research to discover therapies for acute myeloid leukemia.
- Exploring collaborations for the development of innovative oncology therapies with potential partners.
Aslan Pharmaceuticals executive team
- Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.Founder, CEO & Executive Director
- Mr. Kiran Kumar AsarpotaCOO & Head of Finance
- Mr. Ben GoodgerGeneral Counsel
- Mr. Stephen DoyleChief Business Officer
- Dr. Alexandre Kaoukhov M.D.Chief Medical Officer
- Charlie HsuInvestor Relations Director
- Chi-Chin WangIR & Corporate Development Director